Amarantus Bioscience's (AMBS) Eltoprazine treatment for adults with ADHD met its primary target in a Phase IIa trial of 47 patients and demonstrated 25% greater efficacy vs a placebo.
No serious adverse events took place, while most of the side effects were "mild of moderate." Still, only 36 subjects completed the study.
Amarantus is reviewing it options for the further advancement of its ADHD program, including business-development possibilities as the company prepares to up-list to a national stock exchange. (PR)